A clinical trial conducted by Moderna is evaluating an investigational booster vaccine that may protect against the COVID-19 Omicron variant.
Trial ID: mRNA-1273-P305 [EudraCT ID: 2022-000063-51]
Estimated Enrolment
3,000 Participants
Trial Details
The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational mRNA-1273.529 booster vaccine that may protect against the COVID-19 Omicron variant. The investigational mRNA-1273.529 booster is being compared to a booster dose of Moderna’s COVID-19 vaccine, Spikevax, which is the vaccine that received conditional marketing authorization in the EU. All participants will receive either mRNA-1273.529 or Spikevax.
With different strains of COVID-19, there is an urgent need to develop vaccination plans that will provide greater protection. A booster vaccine that protects against COVID-19 variants, including the Omicron variant, would be a crucial public health tool to help curb the pandemic.
Eligibility criteria
Participants must:
- Be 16 years of age or older
- Be in good health
- Have previously received two or three doses of the COVID-19 vaccine
- Participants who have previously received a third dose must have received an mRNA vaccine (Moderna, Pfizer/BioNTech) as a third dose
- Participants who have previously received two doses may have received mRNA (Moderna, Pfizer/BioNTech) or non-mRNA (Oxford/AstraZeneca, Janssen) vaccines
If you are interested in taking part in this trial, please check your eligibility by completing our pre-screening questionnaire, found here: Citeline Connect (trialscope.com)